Brazil stem cell research & development plan drives embryo register:
This article was originally published in Clinica
Executive Summary
Brazil is consulting on the creation and operation of a national human embryo register that will form the basis for the co-ordination and surveillance of therapeutic and research uses of all embryonic tissue. The plans proposed by healthcare regulatory agency Anvisa are that SisEmbrio be used to register all embryos surplus to IVF treatment and information on the tissues derived from them, including stem cells, for a period of 20 years. The handling of the embryos and the management and submission of their data to SisEmbrio will be the responsibility of the BCTG network of cell and regenerative tissue banks. The register will automatically generate a unique code for each embryo and record data on their subsequent use. Anvisa will be responsible for SisEmbrio. The 30-day consultation ends August 26.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.